ACCESS BIO, INC. Funds and ETFs Access Bio, Inc.
Equities
A950130
KR8840090003
Medical Equipment, Supplies & Distribution
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7,180 KRW | -3.36% |
|
+4.66% | -19.96% |
| 2023 | Access Bio, Inc. acquired an unknown minority stake in CuraPatient Inc. | CI |
| 2023 | Tranche Update on Access Bio, Inc.'s Equity Buyback Plan announced on March 24, 2022. | CI |
Access Bio, Inc. is engaged in research, development and manufacturing of in vitro rapid diagnostic tests, biosensors and molecular diagnostic products. Its product list includes covid-19 detection kits, rapid diagnostic tests, analyzers and molecular diagnostics. Its covid-19 detection kits include CareStart COVID-19 Antigen Home Test, CareStart COVID-19 Antigen, CareStart COVID-19 MDx RT-PCR, CareStart COVID-19 lgM/lgG and CareStart EZ COVID-19 lgM/lgG. Its rapid diagnostic tests include CareStart EZ HIV, CareStart Flu A&B Plus+, CareStart G6PD RDT, CareStart Malaria RDT, CareStart Dengue RDT, care US HIV 1/2 and care US Syphilis. The analyzers include care SURE Analyzer 100, care SURE A1c Cartridge, care SURE ACR Cartridge, care SURE CRP Cartridge, care START S1 Analyzer and care START G6PD Biosensor. The molecular diagnostics include care GENE HPV Screening kit-H, care GENE Zika Virus RT-PCR kit, care GENE STD detection kit, care GENE Dengue Virus genotyping kit and others.
Calendar
2024-08-12
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -19.96% | 186M | |
| -5.27% | 12.32B | |
| -3.86% | 8.07B | |
| +33.66% | 5.52B | |
| -7.35% | 4.21B | |
| -55.63% | 2.99B | |
| +13.62% | 2.73B | |
| -3.65% | 2.43B | |
| +30.67% | 2.29B | |
| -4.31% | 1.89B |
- Stock Market
- Equities
- A950130 Stock
- Funds and ETFs Access Bio, Inc.